Congratulations to our Northeastern University co-ops on completing their co-op term at Editas Medicine! We have enjoyed having you at Editas and are so proud of all of your accomplishments. We wish you all the best as you go on to do great things! #InsideEditas #biotechnology #geneediting
Congratulations Bhargava Udayagiri Raghunath 🥂
We had a great month filled with Pride celebrations at Editas Medicine! We are proud to show our support as allies and members of the LGBTQ community. #InsideEditas
Next week, our offices will be closed for our annual summer shutdown. We hope our Editors have a safe and happy week off and enjoy some well-deserved rest and relaxation! #InsideEditas
Yesterday, our team of Editors united in support of our blood drive, hosted in recognition of #WorldSickleCellDay. Together, we collected more than 40 pints of blood. Thank you to all who donated, organized the drive, and extended their support. #ShinetheLightonSickleCell
This #Juneteenth, we unite for #WorldSickleCellDay. Sickle cell disease, a blood disorder, disproportionately affects people of African descent. People with the condition often need blood transfusions during a sickle cell crisis. Editas is closed today in observance of Juneteenth and tomorrow we are hosting a blood drive in recognition of the sickle cell community. #ShinetheLightonSickleCell
With #WorldSickleCellDay coming up on June 19, the Editas Medicine team is honored to listen and learn from Jacqueline Haley, Executive Director at Massachusetts Sickle Cell Association, as she shares why this day is so important and offers inspiration to get involved. This week, our team members will take part in a blood drive to raise awareness and show our support for people with sickle cell disease who rely on blood transfusions as a mainstay of treatment. #ShinetheLightonSickleCell
Today, Editas Medicine President & CEO Gilmore O’Neill sat down with industry leaders to discuss targeted licensing and acquisitions at the Longwood Healthcare Leaders Spring MIT. #longwoodhealthcareleaders #biotechnology
Wonderful insights on M&A and licensing shared by David Meek, Editas Medicine CEO Gilmore ONeill, Servier Pharmaceuticals CBO Deniz Razon Arbor Biotechnologies CEO Devyn Smith & Fish & Richardson P.C. Caleb Bates, JD, PhD
Yesterday, we reported new safety and efficacy data from the RUBY trial of reni-cel in 18 patients with sickle cell disease at #EHA2024. Learn more: bit.ly/3VikpC6 #EHA2024 #geneediting #sicklecelldisease
Good morning from #EHA2024! Today, we are presenting clinical data from the RUBY trial of reni-cel for the treatment of severe sickle cell disease. Learn more: bit.ly/3VikpC6 #sicklecelldisease #geneediting #biotechnology
Aspiring Cell PD Bioengineer-Cell and Tissue Engineering
2wIt has been an absolute pleasure!!